• lung emblem
  • imageBanner

Why choose UNC?

UNC's status as a major research hospital offers important advantages to patients undergoing lung transplants, including access to leading-edge innovations that may improve the likelihood of a successful transplant.

UNC is one of only a few programs in the world conducting research in the field of ex-vivo lung perfusion. This highly specialized technique allows the medical team to take lungs that might traditionally be considered unsuitable for transplant, and repair them outside the donor before transplanting them into the patient. The Principal Investigator for this research is Dr. Thomas Egan, and the Co-Investigators are Drs. Peader Noone and Benjamin Haithcock. Advances in this field will allow us to both increase the number of lung donors, and improve the quality of the tissues donated, an especially important step forward because of the damage that often occurs to otherwise-healthy lungs during end-of-life treatment.

Patients here also benefit from our strong emphasis on collaboration between clinical and research teams throughout the hospital. That collaboration has led to importance advances in immunosuppressive medicines for transplant patients, along with the creation of a special team dedicated to preventing infections in transplant patients.

Surgeons, physicians, and researchers on the lung transplant team at UNC have more than 200 published manuscripts, and scores of contributions in a wide range of medical publications to their credit, confirming their status as leaders among their lung-transplant peers.

The recently expanded bed capacity at UNC allows us to serve a greater number of transplant patients. In addition, our efficient patient-transfer process allows us to see new patients within 24 hours of referral in most cases.

Emergency air transport is available through Carolina Air Care, which offers both helicopter and fixed-wing service.